View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

IO 360° Speaker RJ Motzer and BMS Featured in Article on FDA Granting Priority Review to Nivolumab for Renal Cell Carcinoma


  • November 19, 2015

  • Congratulations to BMS on receiving priority review for Opdivo in renal cell carcinoma. Final approval for the application will be made by March 16, 2016.

    Immuno-Oncology 360° (IO360°) speaker and lead author of the NEJM article on renal cell carcinoma, Dr. RJ Motzer of Memorial Sloan Kettering Cancer Center comments on Nivolumab toxicity stating:

    Nivolumab showed a favorable toxicity profile, with fewer grade 3 or 4 adverse events compared to everolimus. One of the previous standouts for everolimus as a popular treatment in kidney cancer was its favorable safety profile, so showing an improvement in the safety profile compared to everolimus is really remarkable.”

    Robert_Motzer

    RJ Motzer, Memorial Sloan Kettering Cancer Center

    Dr. Motzer will be delivering an in depth talk on the most current phase III data for Nivolumab for Renal Cell Carcinoma at the 2nd Annual Immuno-Oncology 360° conference taking place February 2-3, 2016 at The New York Academy of Medicine, NYC

    To read the full article visit: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-nivolumab-for-renal-cell-carcinoma

    For more information on the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/